Quest LaboratoriesNSE:QUESTLAB -1.56%44 Return-on-Tangible-Asset is 9.86% as of Mar. 2026, which is 29% below its 10-year median of 13.90. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 8 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Quest Laboratories ranks worse than 52.94% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Quest Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹114.8 Mil. Quest Laboratories's average total tangible assets for the quarter that ended in Mar. 2026 was ₹1,164.0 Mil. Therefore, Quest Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 9.86%.
The historical rank and industry rank for Quest Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
NSE:QUESTLAB'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.47 Med: 13.9 Max: 18.56
Current: 2.47
During the past 6 years, Quest Laboratories's highest Return-on-Tangible-Asset was 18.56%. The lowest was 2.47%. And the median was 13.90%.
NSE:QUESTLAB's Return-on-Tangible-Asset is ranked worse than 52.94% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs NSE:QUESTLAB: 2.47
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Quest Laboratories Return-on-Tangible-Asset Related Terms
Quest Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.86% mean?
Quest Laboratories (NSE:QUESTLAB) has a Return-on-Tangible-Asset of 9.86% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Quest Laboratories and its competitors. This is 29% below median its historical median of 13.90. Over the past decade, Quest Laboratories' Return-on-Tangible-Asset has ranged from 2.47 to 18.56. According to the industry distribution chart, Quest Laboratories ranks #531 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 52.9%.
Is Quest Laboratories' Return-on-Tangible-Asset too high?
Quest Laboratories' current Return-on-Tangible-Asset of 9.86% is 29% below median its 10-year median of 13.90. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 18.56. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.13. Quest Laboratories' value of 9.86% is 215% above this industry median. Based on the distribution chart, Quest Laboratories ranks #531 out of 1003 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #531 out of 1003 companies for Return-on-Tangible-Asset. This places Quest Laboratories in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.13. Quest Laboratories' value of 9.86% is 215% above this benchmark. Historically, Quest Laboratories' own Return-on-Tangible-Asset has ranged from 2.47 to 18.56 over the past decade. While the company's 10-year median is 13.90 vs. the industry median of 3.13, Quest Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.13, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current Return-on-Tangible-Asset of 9.86% is 215% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current Return-on-Tangible-Asset is 9.86%, which is 29% below median its own 10-year median of 13.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current Return-on-Tangible-Asset of 9.86%. The current Return-on-Tangible-Asset is 9.86%, which is 29% below median its 10-year median of 13.90 and 215% above the Drug Manufacturers industry median of 3.13. Quest Laboratories' overall GF Score™ is 44/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current Return-on-Tangible-Asset is 9.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score
Get the complete analysis for NSE:QUESTLAB
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 